Triple-negative breast cancer (TNBC) is characterized by limited pharmaceutical treatment options as therapy relevant expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) is missing. Here, ESR1 is linked to triple-negative breast carcinoma.